KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals, Inc. was a biopharmaceutical company focused on small-molecule protease inhibitors for diseases with high unmet need. Its research began in the United Kingdom, where the company was founded around 2009 with a base near Salisbury, and it later maintained corporate offices in Cambridge, Massachusetts. The company concentrated on the plasma kallikrein pathway, which is involved in hereditary angioedema (HAE) and certain eye diseases.

KalVista became a U.S.-listed company in 2017 through a merger with Carbylan Therapeutics, and its shares traded on Nasdaq under the symbol KALV. Its fiscal year ended April 30. Early programs included KVD001, an injectable candidate studied in diabetic macular edema, and KVD824, an oral candidate for HAE prevention that was discontinued after clinical findings. The company then concentrated its resources on sebetralstat, an oral plasma kallikrein inhibitor.

Sebetralstat was developed as an on-demand oral treatment for HAE attacks, a rare genetic disorder causing recurrent episodes of swelling. The company reported positive results from its pivotal KONFIDENT trial, filed for regulatory approval, and in July 2025 the U.S. Food and Drug Administration approved the product under the name EKTERLY, described as the first oral on-demand therapy for HAE. Approvals and launches in other regions followed, and KalVista built a commercial organization in the United States.

The company funded its development through equity offerings, royalty-type financing and collaboration arrangements, and its stock price rose as sebetralstat advanced toward the market. A commercial launch carried significant costs, and KalVista reported net losses as it built sales and marketing capability. In April 2026, the company announced a definitive agreement under which Chiesi Group, the Italian pharmaceutical company, would acquire it.

Under the agreement, a Chiesi subsidiary, Skyline Merger Sub, Inc., commenced a tender offer on May 13, 2026 to buy all outstanding shares for $27.00 per share in cash, without interest. The offer expired at 11:59 p.m. Eastern Time on June 10, 2026, with approximately 77.8 percent of outstanding shares, or about 43.15 million shares, validly tendered, satisfying the minimum condition.

Chiesi then completed the acquisition on June 11, 2026 through a merger under Section 251(h) of the Delaware General Corporation Law, which did not require a stockholder vote. KalVista survived as a wholly owned subsidiary of Chiesi. Nasdaq trading in KALV stopped before the market opened that day, and the company requested the filing of a Form 25 and planned to file a Form 15 to end its SEC reporting obligations. Chiesi, a privately held group with a focus on respiratory, rare disease and specialty care, gained control of the commercial EKTERLY product and the remaining KalVista research pipeline through the purchase.